Ovarian cancer can be cured, but the chance depends heavily on what stage it was found at and what type it is

Ovarian cancer is curable, especially when caught early. A woman diagnosed with stage 1 ovarian cancer—cancer confined to one or both ovaries—has roughly a 90% five-year survival rate. But most ovarian cancers are found at stage 3 or 4, when the cancer has spread beyond the ovaries into the abdomen or elsewhere. At stage 4, the five-year survival rate drops to around 30%. The word "curable" means different things depending on when the cancer was found and how the body responds to treatment.

The type of ovarian cancer also matters. High-grade serous carcinoma, the most common form, behaves differently from clear cell or mucinous types. Some women with advanced ovarian cancer go into remission for years after chemotherapy and surgery, then relapse. Others remain in remission long-term. Doctors use the term "remission" rather than "cured" in many cases because ovarian cancer can return even after years without symptoms.

Key Takeaways

  • Stage 1 ovarian cancer has a roughly 90% five-year survival rate; stage 4 has roughly 30%, so early detection significantly changes outcomes.
  • Treatment usually combines surgery to remove the tumor and chemotherapy, sometimes with newer drugs that target specific mutations or boost the immune system.
  • Many women with advanced ovarian cancer enter remission after treatment but face the possibility of recurrence, which is why doctors distinguish between remission and cure.
  • Genetic mutations like BRCA1 or BRCA2 affect both risk and treatment options, and testing for these is now standard for most ovarian cancer diagnoses.

How stage affects the chance of cure

Stage describes how far the cancer has spread at the time of diagnosis. Stage 1 means the cancer is in one or both ovaries only. Stage 2 means it has spread to other organs in the pelvis. Stage 3 means it has spread to the lining of the abdomen or to lymph nodes in the abdomen. Stage 4 means it has spread to distant organs like the liver, lungs, or brain, or to fluid around the lungs.

The five-year survival rate—the percentage of people alive five years after diagnosis—is roughly 90% for stage 1, 70% for stage 2, 40% for stage 3, and 30% for stage 4. These numbers reflect averages across all types of ovarian cancer and all ages. An individual woman's outcome depends on her specific tumor, her age, her overall health, and how well her cancer responds to the drugs used to treat it. Some women with stage 4 cancer live much longer than the average; others do not.

What treatment for ovarian cancer involves

Standard treatment for ovarian cancer is surgery followed by chemotherapy. The surgery aims to remove as much of the tumor as possible—ideally all of it, a goal called "optimal debulking." A gynecologic oncologist removes the ovaries, fallopian tubes, and uterus, and may remove other organs or tissue if cancer has spread there. The more completely the surgeon can remove the tumor, the better the chemotherapy tends to work.

Chemotherapy after surgery kills cancer cells that may remain. The most common regimen is carboplatin plus paclitaxel, given intravenously every three weeks for six cycles. Newer treatments have changed outcomes for some women. If the tumor has a BRCA1 or BRCA2 mutation, or shows a pattern called "homologous recombination deficiency," drugs called PARP inhibitors (such as olaparib or niraparib) can extend the time before the cancer returns. If the tumor has high levels of a protein called PD-L1, immunotherapy drugs may help. Some women receive bevacizumab, a drug that blocks blood vessel growth to tumors, alongside or after chemotherapy.

For women whose cancer returns after initial treatment, chemotherapy can be given again, sometimes with different drugs. Some recurrent cancers respond well to a second round of treatment; others do not. The goal shifts from cure to extending life and managing symptoms.

The difference between remission and cure

In cancer medicine, remission means the cancer is no longer visible on imaging or in blood tests. Cure means the cancer will not return. For ovarian cancer, doctors rarely use the word "cure" because the cancer can come back years or even decades later, even after successful initial treatment.

A woman might have no sign of cancer for five years, ten years, or longer, then develop recurrent ovarian cancer. This happens in roughly 70% of women with advanced ovarian cancer, though the timing varies widely. Some recurrences happen within a year; others happen after many years of remission. Because of this pattern, doctors describe outcomes in terms of progression-free survival (how long before the cancer grows again) and overall survival (how long the woman lives), rather than cure rates.

That said, some women with early-stage ovarian cancer who are treated with surgery and chemotherapy never have a recurrence. For them, the cancer is effectively cured, even if doctors do not use that exact word.

Genetic testing and personalized treatment

Testing for BRCA1 and BRCA2 mutations is now standard for most women diagnosed with ovarian cancer. These genes normally help repair damaged DNA. When mutated, they increase the risk of ovarian and breast cancer. If a woman's tumor carries a BRCA mutation, she has more treatment options and often a better prognosis because her cancer tends to respond well to PARP inhibitors.

Beyond BRCA, doctors now test ovarian cancers for other mutations and patterns that predict which drugs will work best. A tumor might have a mutation in the TP53 gene, or show microsatellite instability, or have a high tumor mutational burden. Each of these findings can point toward a specific treatment. This approach, called precision medicine, has improved outcomes for some women but does not work equally well for all tumor types.

If a woman is found to carry a BRCA mutation, her relatives may also be at higher risk and may choose to be tested. Some women with a BRCA mutation who have not had cancer choose preventive surgery to remove their ovaries and fallopian tubes, which substantially lowers their risk.

What happens after treatment ends

After completing chemotherapy, a woman with ovarian cancer enters a period of monitoring. She sees her oncologist every few months for the first year or two, then less frequently if she remains in remission. Monitoring includes physical exams and blood tests for a tumor marker called CA-125, which can rise if cancer is returning. Imaging such as CT scans may be done if symptoms develop or if CA-125 rises.

Some women experience long-term side effects from chemotherapy, including nerve damage (neuropathy), hearing loss, or heart problems. Others have no lasting effects. Fertility is affected: chemotherapy damages eggs, so most women treated for ovarian cancer cannot become pregnant afterward. Surgical removal of the ovaries causes immediate menopause, with hot flashes, vaginal dryness, and other symptoms that can be managed with hormone therapy or other medications.

Clinical trials and emerging treatments

Research into ovarian cancer treatment is ongoing. Clinical trials are testing new combinations of chemotherapy, new immunotherapy drugs, and new targeted therapies. Some trials focus on preventing recurrence in women who have completed initial treatment. Others test treatments for women whose cancer has returned.

Women interested in clinical trials can search the National Cancer Institute's database at cancer.gov or ask their oncologist whether a trial might be appropriate. Trials offer access to newer drugs before they are widely available, though there is no may provide the new drug will work better than standard treatment.

Frequently Asked Questions

Can ovarian cancer come back after five years of remission?

Yes. While many recurrences happen within the first two years, ovarian cancer can return after five, ten, or more years without symptoms. This is why doctors monitor women long-term rather than declaring them cured after a set period.

What is the survival rate for stage 3 ovarian cancer?

The five-year survival rate for stage 3 ovarian cancer is roughly 40%. This means about 40% of women diagnosed with stage 3 ovarian cancer are alive five years later. Individual outcomes vary based on how well the tumor responds to treatment and other factors.

Does having a BRCA mutation make ovarian cancer harder to treat?

No—it is the opposite. BRCA-mutated ovarian cancers typically respond very well to chemotherapy and to PARP inhibitors, which can extend remission. Having a BRCA mutation usually means more treatment options and often a better prognosis than BRCA-negative cancers.

Can ovarian cancer be prevented if I have a BRCA mutation?

Surgical removal of the ovaries and fallopian tubes reduces the risk of ovarian cancer by roughly 95% in women with a BRCA mutation. This is a major decision with its own effects, including immediate menopause. Discuss the risks and benefits with a genetic counselor and oncologist.

What should I ask my oncologist about my specific prognosis?

Ask about your cancer's stage, type, and genetic mutations; how completely the surgeon removed the tumor; which chemotherapy drugs you will receive; whether you are a candidate for PARP inhibitors or immunotherapy; and what the expected progression-free and overall survival rates are for someone with your specific cancer.